Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-07-02 | Amended | $10,879,308 | $3,675,587 | Equity Only | 06b | SEC link |
| 2024-07-02 | Amended | $7,203,721 | $1,175,000 | Equity Only | 06b | SEC link |
| 2023-12-21 | Amended | $6,028,721 | $2,825,000 | Equity Only | 06b | SEC link |
| 2022-12-22 | Amended | $3,203,721 | $0 | Equity Only | 06b | SEC link |
| 2022-11-10 | Amended | $3,203,721 | $898,721 | Equity Only | 06b | SEC link |
| 2021-11-10 | Amended | $2,305,000 | $876,250 | Equity Only | 06b | SEC link |
| 2020-12-23 | Amended | $1,428,750 | $698,750 | Equity Only | 06b | SEC link |
| 2020-07-14 | Amended | $730,000 | $285,000 | Equity Only | 06b | SEC link |
| 2019-07-09 | New | $445,000 | $445,000 | Equity Only | 06b | SEC link |
| 2017-09-05 | Amended | $34,803,641 | $3,463,000 | Equity Only | 06b | SEC link |
| 2015-11-16 | New | $31,340,641 | $31,340,641 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Abid Ansari | Executive |
| Henry Esber | Director |
| Arnold Glazier | Director, Executive |
| Jeffrey Aaron Glazier | Director, Executive |
| Gregg Goldstein | Director, Executive |
| Michael J. Petit | Director |
| Barry Seeman | Director |
| Michael D. Sigman | Director |